Eliana Merle
Stock Analyst at UBS
(2.06)
# 2,902
Out of 4,761 analysts
75
Total ratings
34.55%
Success rate
-1.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $109 → $113 | $69.43 | +62.75% | 2 | Feb 20, 2025 | |
| MRNA Moderna | Maintains: Buy | $96 → $78 | $34.09 | +128.81% | 6 | Feb 19, 2025 | |
| ETNB 89bio | Maintains: Buy | $25 → $38 | $11.19 | +239.59% | 3 | Jan 31, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $42 → $109 | $51.34 | +112.31% | 4 | Jan 31, 2025 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Neutral | $5 → $2.2 | $2.52 | -12.70% | 4 | Jan 28, 2025 | |
| RVMD Revolution Medicines | Maintains: Buy | $65 → $71 | $42.37 | +67.57% | 2 | Jan 8, 2025 | |
| ASND Ascendis Pharma | Initiates: Buy | $196 | $152.43 | +28.58% | 1 | Jan 7, 2025 | |
| TYRA Tyra Biosciences | Initiates: Buy | $28 | $12.99 | +115.55% | 1 | Jan 7, 2025 | |
| SGMT Sagimet Biosciences | Initiates: Buy | $12 | $4.06 | +195.57% | 1 | Nov 12, 2024 | |
| IVA Inventiva | Initiates: Neutral | $3 | $2.78 | +7.91% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $6.71 | +287.77% | 1 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $74 | $38.16 | +93.92% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $411 → $441 | $346.76 | +27.18% | 3 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $18.93 | +74.37% | 4 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $117.94 | +11.07% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $2 | $1.26 | +58.73% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $83 | $28.30 | +193.34% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $253 → $288 | $251.69 | +14.43% | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $36.87 | +27.49% | 2 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $4.81 | +4.06% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $18 | $4.14 | +334.78% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $42 | $12.96 | +224.07% | 4 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $18 | $3.31 | +444.63% | 1 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $1.48 | +442.37% | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $6.61 | +232.97% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $7.33 | +541.64% | 1 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $9.03 | +77.19% | 2 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $123 | $18.40 | +568.48% | 3 | May 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $192 → $134 | $26.99 | +396.57% | 3 | Aug 19, 2020 |
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Buy
Price Target: $109 → $113
Current: $69.43
Upside: +62.75%
Moderna
Feb 19, 2025
Maintains: Buy
Price Target: $96 → $78
Current: $34.09
Upside: +128.81%
89bio
Jan 31, 2025
Maintains: Buy
Price Target: $25 → $38
Current: $11.19
Upside: +239.59%
Akero Therapeutics
Jan 31, 2025
Maintains: Buy
Price Target: $42 → $109
Current: $51.34
Upside: +112.31%
Zentalis Pharmaceuticals
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $2.52
Upside: -12.70%
Revolution Medicines
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $42.37
Upside: +67.57%
Ascendis Pharma
Jan 7, 2025
Initiates: Buy
Price Target: $196
Current: $152.43
Upside: +28.58%
Tyra Biosciences
Jan 7, 2025
Initiates: Buy
Price Target: $28
Current: $12.99
Upside: +115.55%
Sagimet Biosciences
Nov 12, 2024
Initiates: Buy
Price Target: $12
Current: $4.06
Upside: +195.57%
Inventiva
Nov 12, 2024
Initiates: Neutral
Price Target: $3
Current: $2.78
Upside: +7.91%
Nov 12, 2024
Initiates: Buy
Price Target: $26
Current: $6.71
Upside: +287.77%
Nov 4, 2024
Maintains: Buy
Price Target: $80 → $74
Current: $38.16
Upside: +93.92%
Nov 1, 2024
Maintains: Buy
Price Target: $411 → $441
Current: $346.76
Upside: +27.18%
Oct 30, 2024
Maintains: Neutral
Price Target: $23 → $33
Current: $18.93
Upside: +74.37%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $117.94
Upside: +11.07%
Sep 9, 2024
Maintains: Neutral
Price Target: $10 → $2
Current: $1.26
Upside: +58.73%
Aug 9, 2024
Maintains: Buy
Price Target: $85 → $83
Current: $28.30
Upside: +193.34%
Jun 28, 2024
Maintains: Buy
Price Target: $253 → $288
Current: $251.69
Upside: +14.43%
May 28, 2024
Maintains: Buy
Price Target: $51 → $47
Current: $36.87
Upside: +27.49%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $4.81
Upside: +4.06%
Mar 27, 2024
Maintains: Buy
Price Target: $19 → $18
Current: $4.14
Upside: +334.78%
May 19, 2023
Maintains: Buy
Price Target: $45 → $42
Current: $12.96
Upside: +224.07%
Jan 19, 2023
Upgrades: Buy
Price Target: $18
Current: $3.31
Upside: +444.63%
Dec 7, 2022
Maintains: Buy
Price Target: $19 → $8
Current: $1.48
Upside: +442.37%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $6.61
Upside: +232.97%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $7.33
Upside: +541.64%
May 21, 2021
Initiates: Buy
Price Target: $16
Current: $9.03
Upside: +77.19%
May 21, 2021
Initiates: Buy
Price Target: $123
Current: $18.40
Upside: +568.48%
Aug 19, 2020
Maintains: Neutral
Price Target: $192 → $134
Current: $26.99
Upside: +396.57%